Drug intelligence / Profile preview

IFX-101

Development stage: Preclinical
Lead developer: Infinimmune
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

IFX-101 is a 'Human-First' monoclonal antibody therapeutic being developed by Infinimmune for the treatment of atopic dermatitis. As the lead candidate in Infinimmune's pipeline, it was discovered using a proprietary platform that identifies rare, high-affinity antibodies from the immune systems of healthy human donors. The drug is designed to provide superior efficacy and extended dosing intervals to enhance patient convenience and quality of life. In 2024, the program advanced toward clinical development through a manufacturing partnership with KBI Biopharma, utilizing their SUREmAb™ platform for cell line development.

Targets

IL22 (Interleukin 22)

Beyond the preview

Go deeper on IFX-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IFX-101.

Explore the full profile